Zia Rahman, MD
Adjunct Assistant ProfessorAbout
Titles
Adjunct Assistant Professor
Biography
Zia Rahman, M.D. a graduate of the Allama Iqbal Medical College in Lahore, Pakistan, received Internal Medicine training in Lahore and at Union Memorial Hospital in Baltimore, Maryland. He then trained as a Pathologist as well as an Internist at the University of Connecticut Health Center and at the State University of New York in Long Island. After completing Fellowship Training in Hematology and Oncology at the Memorial Sloan-Kettering Cancer Center in New York, he joined the University of Texas MD Anderson Cancer Center as an Assistant Professor of Medicine. There he coordinated the Multidisciplinary Breast Clinic and served as an Attending Physician in the Departments of Breast Medical Oncology and Blood and Marrow Transplantation.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Medical Oncology and Hematology
- Yale Cancer Center
Education & Training
- MD
- Allama Iqbal Medical College (1982)
Research
Clinical Trials
Current Trials
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
HIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2025Recruiting ParticipantsGenderMaleAge18+ yearsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsA Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
HIC ID2000029678RoleSub InvestigatorPrimary Completion Date12/15/2023Recruiting ParticipantsLUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
HIC ID2000025282RoleSub InvestigatorPrimary Completion Date01/28/2029Recruiting Participants